Dyadic International’s (DYAI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $6.00 price target on the biotechnology company’s stock.

Dyadic International Stock Performance

Shares of DYAI stock traded down $0.02 during mid-day trading on Thursday, hitting $1.12. The stock had a trading volume of 31,970 shares, compared to its average volume of 47,639. Dyadic International has a 12-month low of $0.93 and a 12-month high of $2.67. The firm’s 50-day moving average is $1.13 and its two-hundred day moving average is $1.42. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.39.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The company had revenue of $1.96 million for the quarter, compared to the consensus estimate of $1.05 million. During the same quarter last year, the company earned ($0.06) earnings per share. Equities analysts anticipate that Dyadic International will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. lifted its position in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 868,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the quarter. Chapin Davis Inc. owned about 2.97% of Dyadic International worth $903,000 as of its most recent SEC filing. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.